

Anti-CD22 (Inotuzumab), Humanized Antibody

rev 10/20

CATALOG NO.: A2179-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a recombinant antibody to Inotuzumab without the drug conjugation. The original antibody-drug conjugate (Inotuzumab Ozogamicin) consists of Anti-CD22 humanized monoclonal antibody that is linked to a cytotoxic drug N-acetyl-gamma-calicheamicin via 4-(4 acetylphenoxy) butanoic acid (acetyl butyrate) linker. Upon internalization in the cell, the drug is detached from the antibody by hydrolytic cleavage. The drug binds to the minor groove of the DNA and forms a diradical species. This diradical species abstracts hydrogen ions from the phosphodiester bonds of DNA and causes double-strand DNA breaks, which leads to cell cycle arrest and apoptosis of the tumorigenic cells. The original ADC is approved by the FDA to treat acute myeloid leukemia. It is also approved to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

ALTERNATE NAMES: CMC 544, CMC-544, CMC544, PF-05208773, WAY-207294, Way 207294, SIGLEC2, SIGLEC-2

ANTIBODY TYPE: Monoclonal

HOST/ISOTYPE: Recombinant / IgG4, kappa

SOURCE: CHO cells

IMMUNOGEN: Human CD22

CAS NUMBER: 635715-01-4

MOLECULAR WEIGHT: 160 kDa

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C. Avoid freeze/thaw cycles

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-CD30 (Brentuximab), Chimeric Antibody (A2177)
 Anti-CD20 (Ofatumumab), Human IgG1 Antibody (A2172)
 Anti-CD79B (Polatuzumab), Humanized Antibody (A2178)
 Anti-PD-L1 (Avelumab), Human IgG1 Antibody (A2152)
 Anti-Nectin-4 (Enfortumab), Human IgG1 Antibody (A2176)

FOR RESEARCH USE ONLY! Not to be used on humans.